Seattle Genetics (SGEN) is surging higher this morning even as the overall markets are sharply lower.  Seattle Genetic shareholders can thank RBC Capital for the surge in the share price today, up $1.00 or about 5.43% at this time. This morning RBC Capital raised their 2011 sales forecast for Adcetris, the flagship therapy for Seattle